Veradermics

Veradermics' VDPHL01 Phase 2 Success Signals Major Shift in Female Pattern Hair Loss Treatment

Veradermics' VDPHL01, an oral extended-release minoxidil, demonstrated significant Phase 2 success in female pattern hair loss, exceeding investor expectations with a 23 hairs/cm² increase. This de-risks its ongoing Phase 3 program, signaling a potential first-in-class oral treatment for women. Procurement and supply chain leaders should assess future minoxidil API demand and monitor competitive innovations in the rapidly evolving hair loss market.